Yahong Pharmaceuticals announced that the company's product APL-1702, used for treating high-grade cervical squamous intraepithelial lesions, had the results of the international multicenter Phase III clinical trial selected for the 2024 International Photodynamic Therapy and Photodiagnosis Conference. The efficacy data on reducing the pathological grading of precancerous cervical lesions were presented in the form of an oral presentation at the conference. The current market application for this product has been accepted by the National Medical Products Administration, but the success of its market launch and timing are uncertain.
亚虹医药：产品APL-1702国际多中心Ⅲ期临床试验结果入选2024年国际光动力与光诊断大会
Yahong Pharmaceuticals: The results of the international multicenter Phase III clinical trial of product APL-1702 were selected for the 2024 International Photodynamic Therapy and Photodiagnosis Conference.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney